Evidence map›Paper›PMID 30958841›Full record

Trial reportPloS one2019

Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.

Caihong Xu, Renzhong Li, Hemant Deepak Shewade, Kathiresan Jeyashree, Yunzhou Ruan, Canyou Zhang, Lixia Wang, Hui Zhang

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. A comprehensive evaluation of a novel targeted-sequencing workflow forFrontiers in cellular and infection microbiology · 2025
    Article
  7. Article
  8. Article
  9. Losses along the tuberculosis sputum sample referral cascade for Mpongwe District, Zambia.African journal of primary health care & family medicine · 2023
    Article
  10. Article
  11. Direct detection of drug-resistantFrontiers in public health · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Caihong XuNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.ORCID 0000-0002-2926-2341
Renzhong LiNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.
Hemant Deepak ShewadeInternational Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Office, New Delhi, India.ORCID 0000-0002-8242-1911
Kathiresan JeyashreeVelammal Medical College Hospital and Research Institute, Madurai, India.
Yunzhou RuanNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.
Canyou ZhangNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.ORCID 0000-0003-1819-5347
Lixia WangNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.
Hui ZhangNational Center for Tuberculosis Control and Prevention, China Center for Disease Control (CDC), Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChina's national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway.

objectiveUnder the Global Fund programmatic management of drug-resistant TB (2006-13), we assessed the attrition and delay in the pathway and the factors associated.

methodsCohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pre-treatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively.

resultsOf 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pre-treatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion 'previously treated' and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion 'treatment after lost to follow up'. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion 'recurrent TB'. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion 'treatment after failure'.

conclusionThe diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.

Indexed as

Mycobacterium tuberculosisTime-to-TreatmentTuberculosis, Multidrug-ResistantAdolescentAdultAgedAntitubercular AgentsChinaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedRisk FactorsAntitubercular Agents

Identifiers

PMID30958841
PMCPMC6453446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.